[go: up one dir, main page]

BRPI9912156B8 - processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina - Google Patents

processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina

Info

Publication number
BRPI9912156B8
BRPI9912156B8 BRPI9912156A BR9912156A BRPI9912156B8 BR PI9912156 B8 BRPI9912156 B8 BR PI9912156B8 BR PI9912156 A BRPI9912156 A BR PI9912156A BR 9912156 A BR9912156 A BR 9912156A BR PI9912156 B8 BRPI9912156 B8 BR PI9912156B8
Authority
BR
Brazil
Prior art keywords
preparation
propylcarbamate
aminophenyl
furanyl
tetrahydro
Prior art date
Application number
BRPI9912156A
Other languages
English (en)
Other versions
BR9912156A (pt
BRPI9912156B1 (pt
Inventor
David Searle Andre
Singh Hardev
Gordon Armitage Ian
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9912156A publication Critical patent/BR9912156A/pt
Publication of BRPI9912156B1 publication Critical patent/BRPI9912156B1/pt
Publication of BRPI9912156B8 publication Critical patent/BRPI9912156B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

''composto, composição farmacêutica, uso de um composto, e, processos para o tratamento de uma infeção por retrovírus em um ser humano e para a preparação de um composto'' a invenção diz respeito a (3s)tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)sulfonil[(isobutil)amino]-1-benzil-2-(fosfonoóxi)propilcarbamato de cálcio, a processos para a sua preparação e a seu uso no tratamento de doenças causadas por retrovírus.
BRPI9912156A 1998-07-18 1999-07-15 processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina BRPI9912156B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound
PCT/EP1999/004991 WO2000004033A1 (en) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Publications (3)

Publication Number Publication Date
BR9912156A BR9912156A (pt) 2001-04-10
BRPI9912156B1 BRPI9912156B1 (pt) 2016-07-26
BRPI9912156B8 true BRPI9912156B8 (pt) 2021-05-25

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912156A BRPI9912156B8 (pt) 1998-07-18 1999-07-15 processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina

Country Status (47)

Country Link
US (3) US6514953B1 (pt)
EP (2) EP1240903A3 (pt)
JP (1) JP3437553B2 (pt)
KR (1) KR100694721B1 (pt)
CN (1) CN1188422C (pt)
AP (1) AP2001002039A0 (pt)
AR (1) AR019388A1 (pt)
AT (1) ATE229964T1 (pt)
AU (1) AU766056B2 (pt)
BG (1) BG105253A (pt)
BR (1) BRPI9912156B8 (pt)
CA (1) CA2337857C (pt)
CO (1) CO5090836A1 (pt)
CZ (1) CZ300447B6 (pt)
DE (1) DE69904600T2 (pt)
DK (1) DK1098898T3 (pt)
DZ (1) DZ2845A1 (pt)
EA (1) EA003191B1 (pt)
EE (1) EE200100038A (pt)
ES (1) ES2189450T3 (pt)
GB (1) GB9815567D0 (pt)
GC (1) GC0000105A (pt)
GE (1) GEP20033030B (pt)
GT (1) GT199900111A (pt)
HR (1) HRP20010046A2 (pt)
HU (1) HU229700B1 (pt)
ID (1) ID28070A (pt)
IL (1) IL140824A (pt)
IS (1) IS5808A (pt)
JO (1) JO2114B1 (pt)
MA (1) MA26660A1 (pt)
MY (1) MY122323A (pt)
NO (1) NO329676B1 (pt)
NZ (1) NZ509291A (pt)
OA (1) OA11706A (pt)
PA (1) PA8477801A1 (pt)
PE (1) PE20000869A1 (pt)
PL (1) PL195736B1 (pt)
PT (1) PT1098898E (pt)
SK (1) SK285311B6 (pt)
SV (1) SV1999000096A (pt)
TN (1) TNSN99145A1 (pt)
TR (1) TR200100111T2 (pt)
TW (1) TWI245770B (pt)
WO (1) WO2000004033A1 (pt)
YU (1) YU3401A (pt)
ZA (1) ZA200100417B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2307533T3 (es) * 1999-10-06 2008-12-01 Tibotec Pharmaceuticals Ltd. Hexahidrofuro(2,3)furan-3-il-n-(3-((1,3-benzodioxol-5-ilsulfonil)(is obuti)amino)-1-bencil-2-hidroxipropil carbamato como inhibidor de la proteasa retroviral.
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
CN101041669A (zh) * 2002-04-26 2007-09-26 吉里德科学公司 非核苷逆转录酶抑制剂
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
EP1620109A2 (en) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20080234288A1 (en) * 2003-09-30 2008-09-25 Kenneth Alan Simmen Hcv Inhibiting Sulfonamides
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
MXPA06006899A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
KR101299399B1 (ko) 2004-06-04 2013-08-22 아피늄 파마슈티컬스, 인크. 치료제, 및 그의 제조 및 사용 방법
HRP20070078A2 (hr) 2004-07-27 2007-05-31 Gilead Sciences Fosfonatni analozi spojeva koji inhibiraju hiv
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
PT2307435E (pt) 2008-07-08 2012-09-19 Gilead Sciences Inc Sais de compostos inibidores de vih
CA2998344C (en) * 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
WO2011001383A1 (en) 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
AU2010296846B2 (en) * 2009-09-16 2013-11-28 Sun Pharmaceutical Industries Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
US20130211108A1 (en) 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
JP2014513044A (ja) * 2011-02-10 2014-05-29 マイラン ラボラトリーズ リミテッド ホスアンプレナビルカルシウム結晶およびその調製方法
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
BR122021020778B1 (pt) 2012-06-19 2022-07-12 Debiopharm International Sa Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
CN107206021B (zh) 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
SI3419628T1 (sl) 2016-02-26 2021-03-31 Debiopharm International Sa Zdravilo za zdravljenje infekcij diabetičnega stopala
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
WO2019027920A1 (en) 2017-08-01 2019-02-07 Gilead Sciences, Inc. CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
PH12021551922A1 (en) 2019-02-14 2022-05-23 Debiopharm Int Sa Afabicin formulation, method for making the same
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
HUP0101598A3 (en) * 1997-12-24 2002-08-28 Vertex Pharmaceuticals Inc Cam Prodrugs of aspartyl protease inhibitors and medicaments containing them
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
CA2346131C (en) * 1998-11-04 2013-01-15 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US6642237B1 (en) * 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

Also Published As

Publication number Publication date
ES2189450T3 (es) 2003-07-01
TR200100111T2 (tr) 2002-02-21
BR9912156A (pt) 2001-04-10
GEP20033030B (en) 2003-07-25
CN1188422C (zh) 2005-02-09
NO20010282L (no) 2001-03-07
PL345620A1 (en) 2002-01-02
KR100694721B1 (ko) 2007-03-15
GB9815567D0 (en) 1998-09-16
HU229700B1 (en) 2014-05-28
IL140824A0 (en) 2002-02-10
YU3401A (sh) 2005-06-10
PE20000869A1 (es) 2000-09-08
EP1098898B1 (en) 2002-12-18
CA2337857A1 (en) 2000-01-27
US20030096795A1 (en) 2003-05-22
US6514953B1 (en) 2003-02-04
EA003191B1 (ru) 2003-02-27
PL195736B1 (pl) 2007-10-31
CZ2001219A3 (cs) 2001-07-11
JP3437553B2 (ja) 2003-08-18
TWI245770B (en) 2005-12-21
NZ509291A (en) 2003-05-30
GT199900111A (es) 2001-01-05
EE200100038A (et) 2002-06-17
DE69904600D1 (de) 2003-01-30
BG105253A (en) 2001-12-29
SK762001A3 (en) 2001-10-08
JO2114B1 (en) 2000-05-21
MY122323A (en) 2006-04-29
ATE229964T1 (de) 2003-01-15
HUP0103432A2 (hu) 2002-04-29
PT1098898E (pt) 2003-04-30
HK1034261A1 (en) 2001-10-19
IL140824A (en) 2004-09-27
NO329676B1 (no) 2010-11-29
CN1324363A (zh) 2001-11-28
ID28070A (id) 2001-05-03
SK285311B6 (sk) 2006-10-05
DZ2845A1 (fr) 2003-12-01
CZ300447B6 (cs) 2009-05-20
ZA200100417B (en) 2002-02-27
PA8477801A1 (es) 2000-05-24
MA26660A1 (fr) 2004-12-20
SV1999000096A (es) 2000-07-06
EP1240903A3 (en) 2003-02-12
NO20010282D0 (no) 2001-01-17
AU766056B2 (en) 2003-10-09
GC0000105A (en) 2005-06-29
TNSN99145A1 (fr) 2005-11-10
CO5090836A1 (es) 2001-10-30
AU5037999A (en) 2000-02-07
BRPI9912156B1 (pt) 2016-07-26
EA200100053A1 (ru) 2001-08-27
HUP0103432A3 (en) 2003-01-28
IS5808A (is) 2001-01-12
HRP20010046A2 (en) 2002-02-28
EP1098898A1 (en) 2001-05-16
CA2337857C (en) 2011-01-25
DE69904600T2 (de) 2003-11-13
JP2003521447A (ja) 2003-07-15
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
OA11706A (en) 2005-01-13
WO2000004033A1 (en) 2000-01-27
DK1098898T3 (da) 2003-04-07
AP2001002039A0 (en) 2001-03-31
EP1240903A2 (en) 2002-09-18
AR019388A1 (es) 2002-02-13

Similar Documents

Publication Publication Date Title
BRPI9912156B8 (pt) processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
MY125821A (en) Pharmaceutical composition of topiramate
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0308901A (pt) ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
BR0308814A (pt) Aminoácidos com afinidade para a proteìna-alfa2gama
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0211063A (pt) Sais de derivados anticonvulsivantes
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR0211635A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
BRPI0410195A (pt) compostos quìmicos
DK440888A (da) Hjaelpestoffer som resorptionsfremmende stoffer af peptider og proteiner ved paafoering paa slimhinder samt anvendelse deraf g praepparat indeholdende hjaelpestofferne
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 11, 13 E 25 COMBINADOS COM O ART. 37 DA LEI 9.279/1996 ( LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/07/2019

B15V Prolongation of time limit allowed